Home
About Us
Pipeline
Investors
News & Events
Careers
| S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values |
| Clinical Trials | R&D Programmes | Technologies & Capabilities | S*BIO’s Functional Capabilities | Publications |
| Investors | Partnerships |
| News & Press Releases | Participation in Events |
| Join Our Team | Job Openings | How to Apply |
 |
 |
|
A new scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its opponents eventually die, and a new generation grows up that is familiar with it. Max Planck |
|
|
|
R&D Programmes HDAC Targeting HDAC Inhibition Using a target driven approach, we are focusing on developing novel and effective inhibitors of histone deacetylases (HDACs), which are implicated in the regulation of genes required for cancer cell proliferation and differentiation. Our R&D team has assembled a comprehensive toolkit around HDACs, comprising enzyme isoforms and molecular tools, which enable us to study the involvement of those isozymes in different disease indications and patient populations. Translating our understanding of these pathways into best-in-class clinical compounds is a fundamental goal of S*BIO. Kinase Programme Kinase inhibition is currently a fertile area of drug discovery research. Through a sophisticated target selection process, we are developing targeted oncology compounds by focusing on Protein Kinases, which have been demonstrated to halt cancer cell growth. Our range of promising kinase inhibitors are currently in the lead optimisation phase.
|